Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Operating Expenses (2020 - 2025)

Tarsus Pharmaceuticals has reported Other Operating Expenses over the past 6 years, most recently at $10.9 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $10.9 million for Q4 2025, up 121.82% from a year ago — trailing twelve months through Dec 2025 was $30.7 million (up 139.23% YoY), and the annual figure for FY2025 was $30.7 million, up 139.23%.
  • Other Operating Expenses for Q4 2025 was $10.9 million at Tarsus Pharmaceuticals, up from $8.3 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for TARS hit a ceiling of $10.9 million in Q4 2025 and a floor of -$24000.0 in Q4 2021.
  • Median Other Operating Expenses over the past 5 years was $3.0 million (2024), compared with a mean of $3.9 million.
  • Biggest five-year swings in Other Operating Expenses: plummeted 99.07% in 2021 and later skyrocketed 41466.67% in 2022.
  • Tarsus Pharmaceuticals' Other Operating Expenses stood at -$24000.0 in 2021, then skyrocketed by 41466.67% to $9.9 million in 2022, then plummeted by 87.75% to $1.2 million in 2023, then soared by 305.1% to $4.9 million in 2024, then skyrocketed by 121.82% to $10.9 million in 2025.
  • The last three reported values for Other Operating Expenses were $10.9 million (Q4 2025), $8.3 million (Q3 2025), and $6.2 million (Q2 2025) per Business Quant data.